Overview Dividends

(CMPS) Compass Pathways - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US20451W1018

Psilocybin, Therapy, Depression, Trials

Health Care Services
Market Cap in USD: 629m

IPO / Inception: 2020-09-18
Return 12m vs S&P 500: 55.5%

EPS (Earnings per Share)

EPS CAGR: 24.73%
EPS Trend: 37.7%

Last SUE: 0.11
Qual. Beats: 0

Revenue

Rev. CAGR: 0.00%
Rev. Trend: 2.8%

Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	86.3%
Value at Risk 5%th	126%
Relative Tail Risk	-11.00%

Reward TTM
Sharpe Ratio	1.04
Alpha	41.65
CAGR/Max DD	-0.08

Character TTM
Hurst Exponent	0.402
Beta	1.123
Beta Downside	1.652

Drawdowns 3y
Max DD	81.00%
Mean DD	41.77%
Median DD	44.34%

Description: CMPS Compass Pathways December 30, 2025

Compass Pathways plc (NASDAQ:CMPS) is a UK-based biotech focused on developing psychedelic-based therapies for mental-health disorders. Its lead candidate, COMP360, is a synthetic psilocybin formulation currently in a Phase III trial for treatment-resistant depression and in Phase II trials for post-traumatic stress disorder and anorexia nervosa.

As of the latest filing, Compass holds approximately $150 million in cash and equivalents, giving it a runway of roughly 18 months at current burn rates. The company’s market capitalization hovers near $500 million, and it is positioned to benefit from the expanding global mental-health market, which is projected to grow at a 5-6% CAGR through 2030. Regulatory momentum is also notable: the FDA has granted Breakthrough Therapy Designation for COMP360, and the upcoming European Medicines Agency (EMA) review could further de-risk the pathway to commercialization.

For a deeper, data-driven assessment of CMPS’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 0.5

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.63 (>2.0%) and ΔFCFTA -20.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.63 (>3.0%) and CFO -161.2m > Net Income -237.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (95.3m) change vs 12m ago 39.39% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 1.49%; Δ -1.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -51.39 (EBITDA TTM -231.3m / Interest Expense TTM 4.51m) >= 6 (WARN >= 3)

Altman Z'' -17.91

(A) 0.18 = (Total Current Assets 242.4m - Total Current Liabilities 197.4m) / Total Assets 255.6m

(B) -2.85 = Retained Earnings (Balance) -728.7m / Total Assets 255.6m

warn (B) unusual magnitude: -2.85 — check mapping/units

(D) -3.41 = Book Value of Equity -742.9m / Total Liabilities 218.0m

Total Rating: -17.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.36

1. Piotroski 0.50pt

2. FCF Yield -33.71%

3. FCF Margin data missing

4. Debt/Equity 0.94

5. Debt/Ebitda 0.65

7. RoE -172.5%

8. Rev. Trend 2.80%

9. EPS Trend 37.73%

What is the price of CMPS shares?

As of January 09, 2026, the stock is trading at USD 7.62 with a total of 2,193,582 shares traded.
Over the past week, the price has changed by +16.34%, over one month by +20.95%, over three months by +15.45% and over the past year by +84.06%.

Is CMPS a buy, sell or hold?

Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.

Strong Buy: 7
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CMPS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	16.8	120.7%
Analysts Target Price	16.8	120.7%
ValueRay Target Price	8.3	8.7%

CMPS Fundamental Data Overview January 05, 2026

P/B = 16.7304
Beta = 1.944
Revenue TTM = 0.0 USD
EBIT TTM = -231.5m USD
EBITDA TTM = -231.3m USD
Long Term Debt = 18.6m USD (from longTermDebt, last quarter)
Short Term Debt = 14.6m USD (from shortTermDebt, last quarter)
Debt = 35.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -150.8m USD (from netDebt column, last quarter)
Enterprise Value = 478.2m USD (628.9m + Debt 35.2m - CCE 185.9m)
Interest Coverage Ratio = -51.39 (Ebit TTM -231.5m / Interest Expense TTM 4.51m)
FCF Yield = -33.71% (FCF TTM -161.2m / Enterprise Value 478.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 174.8k) / Revenue TTM)
Tobins Q-Ratio = 1.87 (Enterprise Value 478.2m / Total Assets 255.6m)
Interest Expense / Debt = 3.12% (Interest Expense 1.10m / Debt 35.2m)
Taxrate = 0.17% (-230.0k / -137.9m)
NOPAT = -231.1m (EBIT -231.5m * (1 - 0.17%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 242.4m / Total Current Liabilities 197.4m)
Debt / Equity = 0.94 (Debt 35.2m / totalStockholderEquity, last quarter 37.6m)
Debt / EBITDA = 0.65 (negative EBITDA) (Net Debt -150.8m / EBITDA -231.3m)
Debt / FCF = 0.94 (negative FCF - burning cash) (Net Debt -150.8m / FCF TTM -161.2m)
Total Stockholder Equity = 137.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -94.37% (Net Income -237.3m / Total Assets 255.6m)
RoE = -172.5% (Net Income TTM -237.3m / Total Stockholder Equity 137.6m)
RoCE = -148.2% (out of range, set to none) (EBIT -231.5m / Capital Employed (Equity 137.6m + L.T.Debt 18.6m))
RoIC = -137.3% (out of range, set to none) (NOPAT -231.1m / Invested Capital 168.3m)
WACC = 9.78% (E(628.9m)/V(664.1m) * Re(10.15%) + D(35.2m)/V(664.1m) * Rd(3.12%) * (1-Tc(0.00)))
Discount Rate = 10.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.04%
Fair Price DCF = unknown (Cash Flow -161.2m)
EPS Correlation: 37.73 | EPS CAGR: 24.73% | SUE: 0.11 | # QB: 0
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.31 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-1.16 | Chg30d=+0.063 | Revisions Net=+1 | Growth EPS=+52.2% | Growth Revenue=+0.0%

Additional Sources for CMPS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle